Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan; Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Asian J Psychiatr. 2024 Nov;101:104210. doi: 10.1016/j.ajp.2024.104210. Epub 2024 Aug 30.
Major depressive disorder (MDD) is a complex mental disorder, potentially linked to the gut-microbiota-brain axis. Probiotics like Lactobacillus plantarum PS128 (PS128) may improve depressive symptoms by modulating the gut microbiota based on our previous open trial. We conducted an 8-week double-blind, placebo-controlled trial to investigate the impact of PS128 on depression severity, markers of inflammation and gut permeability, and the gut microbiota composition in 32 patients with MDD with stable antidepressant treatment but moderate symptom severity. Following the 8-week intervention, both the Hamilton Depression Rating Scale-17 score (HAMD), and Depression and Somatic Symptoms Scale (DSSS) showed a significant decrease in both groups (p<0.001). However, there was no significant difference in the change of depression severity between groups (p=0.203). Moreover, alterations in serum levels of high sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-α, and intestinal fatty acid binding protein, as well as changes in the gut microbiota composition, did not exhibit significant differences before and after intervention or between the groups. In comparison to the placebo group, our study did not find significant effects of PS128 on depressive symptoms, biomarkers of inflammation and gut permeability, and the overall gut microbiota composition. Nonetheless, we observed a potential impact of PS128 on the symbiosis of specific taxa. To comprehensively understand the psychophysiological effects of PS128 in patients with MDD, further research with a larger sample size is imperative.
重度抑郁症（MDD）是一种复杂的精神障碍，可能与肠道微生物群-脑轴有关。基于我们之前的开放试验，像植物乳杆菌 PS128（PS128）这样的益生菌可能通过调节肠道微生物群来改善抑郁症状。我们进行了一项为期 8 周的双盲、安慰剂对照试验，以调查 PS128 对 32 名 MDD 患者的抑郁严重程度、炎症和肠道通透性标志物以及肠道微生物群组成的影响，这些患者在接受稳定的抗抑郁治疗但症状中度的情况下。在 8 周的干预后，汉密尔顿抑郁评定量表-17 评分（HAMD）和抑郁和躯体症状量表（DSSS）在两组中均显著下降（p<0.001）。然而，两组之间的抑郁严重程度变化没有显著差异（p=0.203）。此外，血清高敏 C 反应蛋白、白细胞介素 6、肿瘤坏死因子-α和肠脂肪酸结合蛋白水平的变化以及肠道微生物群组成的变化在干预前后或两组之间均无显著差异。与安慰剂组相比，我们的研究没有发现 PS128 对抑郁症状、炎症和肠道通透性生物标志物以及整体肠道微生物群组成有显著影响。尽管如此，我们观察到 PS128 对特定分类群共生的潜在影响。为了全面了解 PS128 对 MDD 患者的心理生理影响，需要进行更大样本量的进一步研究。
